Eversense CGM approved for Treatment Decisions

Continuous glucose monitoring (CGM) uses interstitial fluid to provide real time glucose readings. Some CGMs have a nonadjunctive dosing indication, which means that users can base treatment decisions on the CGM reading.

Most recently, Eversense CGM received the nonadjunctive indication from the FDA. This means that Eversense users will not have to check fingersticks to make treatment decisions in the near future.

Photo 2018 FDA Website

However, users will still need to calibrate the Eversense CGM twice daily and will need to download a new app before they can base treatment on the CGM readings.

The Eversense is the first long-term implantable CGM device that can be used for up to 90 days before replacing. The sensor is inserted via an in-office procedure in the upper arm by a trained physician. A fluorescent chemical coating on the outside of the sensor generates a small amount of light in response to the amount of sugar that is present in fluid under the skin (interstitial glucose). This light signal is converted into a glucose reading and transmitted wirelessly every five minutes to a compatible mobile device.

Read more in Endrocrine Today – FDA approves nonadjunctive indication for Eversense CGM.

For more information visit the Eversense Website


Want more practice for the exam? Try our new Technology Toolkit, meant to assist with studying based on the updated CDE content outline!

Earn 3 CEs and join coach Beverly for her second airing of the Toolkit Live on September 11 and 13, 2019. Purchase includes On-Demand viewing now and the ability to join live later.

Two Online Courses are included in this Technology Toolkit:

  • Tech 101 – Pumps and Sensors Update and Overview and 
  • Tech 102 – Insulin Pump Calculations: From Basal to Square Bolus 

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!